Brought to you by 
Lepu Biotech reigns in $131mm via Series A round
24 Jun 2021
Executive Summary
Lepu Biotechnology Co. Ltd. (immuno-oncology division of Lepu Medical Technology (Beijing) Co. Ltd.) raised $131mm through its Series A round from investors including Shiyu Capital (lead), Suzhou Mingtou, Sumin Investment, China Development Bank, Suzhou Shareate Group, and the company's parent Lepu Medical.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lepu Biotech reigns in $131mm via Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice